Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

Abstract:

:The aim of this systematic review was to collect all current data on indirect costs related to inflammatory bowel disease as well as assessing homogeneity and comparability, and conducting a meta-analysis. Costs were collected using databases from Medline, Embase and Centre for Reviews and Dissemination databases, then average annual cost per patient was calculated and expressed in 2013-rate USD using the consumer price index and purchasing power parity (scenario 1) and then adjusted to specific gross domestic product (scenario 2) to make them comparable. The studies were then included in quantitative synthesis using the meta-analysis and bootstrap methods. This systematic review was carried out and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. From 18 publications, overall annual indirect costs per patient as a result of the quantitative synthesis among all studies eligible for meta-analysis ranged from US$2425.01-US$9622.15 depending on the scenario and model used for analysis. The cost of presenteeism was assessed in only two studies. Considering heterogeneity among all identified studies random-effect model presented the most accurate results of meta-analysis equal to US$7189.27 and US$9622.15 per patient per year for scenario 1 and scenario 2, respectively. This systematic review revealed the existence of a relatively small number of studies that reported on the great economic burden of the disease upon society. A great variety of methodologies and cost components resulted in a very large discrepancy in indirect costs and made meta-analysis difficult to perform, so two scenarios were considered and meta-analysis conducted in subgroups to make data more comparable.

authors

Kawalec P,Malinowski KP

doi

10.1586/14737167.2015.1011130

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

253-66

issue

2

eissn

1473-7167

issn

1744-8379

journal_volume

15

pub_type

杂志文章,meta分析,评审
  • The challenges of implementing pharmacogenomic testing in the clinic.

    abstract:INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2017.1385395

    authors: Moyer AM,Caraballo PJ

    更新日期:2017-12-01 00:00:00

  • Health economics of percutaneous hemodynamic support in the treatment of high-risk cardiac patients: a systematic appraisal of the literature.

    abstract::This article systematically appraises the findings and conclusions derived from six recent studies of the economic impact and relative value of using percutaneous ventricular assist devices to render short-term hemodynamic support to high-risk patients with particular attention to the settings of cardiogenic shock and...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.908714

    authors: Maini B,Scotti DJ,Gregory D

    更新日期:2014-06-01 00:00:00

  • Quality of care of asthma during pregnancy.

    abstract::The goal of asthma management during pregnancy is to keep the mother symptom free and to prevent complications in the fetus. Asthma is a common chronic condition in pregnancy that, if inadequately treated, has the potential to cause adverse effects for both mother and fetus. Aggressive treatment during pregnancy can d...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.1.67

    authors: Streck MR,Blaiss MS

    更新日期:2006-02-01 00:00:00

  • Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?

    abstract::The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.2.145

    authors: Orlewska E

    更新日期:2006-04-01 00:00:00

  • The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

    abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1282316

    authors: Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

    更新日期:2017-08-01 00:00:00

  • Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples.

    abstract:OBJECTIVE:This systematic review and meta-analysis aimed to reassess the effectiveness of condoms in reducing heterosexual transmission of HIV. METHODS:Medline, Scopus, and the ISI Web of Science databases were searched up to June 2014. Eligible studies were synthesized using random-effects models. RESULTS:Twenty-fiv...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737167.2016.1102635

    authors: Giannou FK,Tsiara CG,Nikolopoulos GK,Talias M,Benetou V,Kantzanou M,Bonovas S,Hatzakis A

    更新日期:2016-08-01 00:00:00

  • How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

    abstract::In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.859525

    authors: Diaby V,Goeree R

    更新日期:2014-02-01 00:00:00

  • A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C.

    abstract::A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.6.577

    authors: Shepherd J,Jones J

    更新日期:2007-12-01 00:00:00

  • Cost analysis and clinical applicability of the Resonance metallic ureteral stent.

    abstract::The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.74

    authors: Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

    更新日期:2010-02-01 00:00:00

  • Interpretation of differential item functioning analyses using external review.

    abstract::Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.22

    authors: Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

    更新日期:2010-06-01 00:00:00

  • Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.

    abstract::Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.2.111

    authors: Gladman DD,Brown RE

    更新日期:2008-04-01 00:00:00

  • The cost-effectiveness of therapies to treat alcohol use disorders.

    abstract:INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1392241

    authors: Rehm J,Barbosa C

    更新日期:2018-02-01 00:00:00

  • Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease.

    abstract::Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/erp.12.21

    authors: Oremus M,Tarride JE

    更新日期:2012-06-01 00:00:00

  • Role of patient and public participation in health technology assessment and coverage decisions.

    abstract::Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.82

    authors: Menon D,Stafinski T

    更新日期:2011-02-01 00:00:00

  • Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.

    abstract::Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.2014.861743

    authors: De Franco AC,Oldridge N

    更新日期:2014-02-01 00:00:00

  • Non-communicating children's pain checklist: better pain assessment for severely disabled children.

    abstract::Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.3.327

    authors: Breau LM

    更新日期:2003-06-01 00:00:00

  • Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials.

    abstract::The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.57

    authors: Hamidou Z,Dabakuyo TS,Bonnetain F

    更新日期:2011-10-01 00:00:00

  • Cost of treating otitis media in Australia.

    abstract:OBJECTIVE:Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). METHODS:Little Australia-w...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.6

    authors: Taylor PS,Faeth I,Marks MK,Del Mar CB,Skull SA,Pezzullo ML,Havyatt SM,Coates HL

    更新日期:2009-04-01 00:00:00

  • Threshold denial rates in prior authorization prescription programs.

    abstract::In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.2.165

    authors: Grant WC,Yoder DM,Mullins CD

    更新日期:2004-04-01 00:00:00

  • New management of the pregnant patient to reduce the risk of transmitting herpes to the newborn.

    abstract::Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.6.783

    authors: Baker DA

    更新日期:2005-12-01 00:00:00

  • Application of electronic medical record data for health outcomes research: a review of recent literature.

    abstract::Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.13.7

    authors: Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

    更新日期:2013-04-01 00:00:00

  • Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review.

    abstract::Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1734455

    authors: Hindelang M,Kirsch F,Leidl R

    更新日期:2020-02-01 00:00:00

  • Risk selection in a regulated health insurance market: a review of the concept, possibilities and effects.

    abstract::The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2013.841546

    authors: van Kleef RC,van de Ven WP,van Vliet RC

    更新日期:2013-12-01 00:00:00

  • Should the patent system for pharmaceuticals be replaced? A theoretical approach.

    abstract::This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.927315

    authors: Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

    更新日期:2014-10-01 00:00:00

  • Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.

    abstract:OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1782748

    authors: Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

    更新日期:2020-07-20 00:00:00

  • Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.

    abstract::Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.957679

    authors: Kotsis K,Voulgari PV,Drosos AA,Carvalho AF,Hyphantis T

    更新日期:2014-12-01 00:00:00

  • Trends in translation requests and arising issues regarding cultural adaptation.

    abstract::Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.27

    authors: Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

    更新日期:2011-06-01 00:00:00

  • Reimbursement agency requirements for health related quality-of-life data: a case study.

    abstract::A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.09.62

    authors: Lloyd A,Wild D,Gallop K,Cowell W

    更新日期:2009-12-01 00:00:00

  • Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.

    abstract:OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.1065734

    authors: Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

    更新日期:2015-01-01 00:00:00

  • The Cancer Outcomes Measurement Working Group: rationale overview and a look to the future.

    abstract::In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.4.407

    authors: Snyder C,Gotay CC,Lipscomb J

    更新日期:2006-08-01 00:00:00